These effects were abrogated by anti-TGF-β antibodies, providing rationale for utilization of TGF-β inhibitors, such as GC1008, which is currently in clinical trials in the setting of renal cell carcinoma and malignant melanoma [52]. Here, TGFB1 is linked to melanoma.